InstalabLoading...
InstalabLoading...
If you have lingering bloating, loose stools, abdominal pain, or unexplained hives that no doctor has been able to pin down, a gut parasite called Blastocystis is one of the most overlooked possibilities. It shows up in human stool more often than almost any other intestinal organism, and standard stool tests miss it routinely.
Whether Blastocystis is causing your symptoms is genuinely complicated. It often lives in healthy people without causing trouble, but in some people, particularly those with certain subtypes or weakened immunity, it can drive chronic gastrointestinal misery and skin problems that resolve once it is treated.
Blastocystis hominis (often just called Blastocystis) is a single-celled organism, technically a protist, that lives in the large intestine. It is not a protein, hormone, or chemical you can measure on a blood panel. The test looks for the organism itself in your stool, either under a microscope, in culture, or by detecting its DNA with a polymerase chain reaction (PCR) test, a method that finds genetic material from the parasite.
There are at least 17 to 28 genetically distinct subtypes of Blastocystis, labeled ST1 through ST28. Subtypes 1 through 4 cause most human infections, with ST3 being the dominant subtype across most regions. The subtype matters because pathogenicity appears to vary: ST1, ST4, and ST7 are more often linked to symptoms and disease, while ST2 is more often found in healthy carriers.
You pick it up the way you would pick up most gut bugs: from contaminated water, food, soil, or environmental exposure. Blastocystis has been detected in animals, water sources, and produce in many regions, and shared subtypes between humans and animals point to possible animal-to-human transmission.
Up to half of infected people stay asymptomatic for months or even years. In a study of 2,800 immunocompetent adults, no correlation was found between the presence of Blastocystis and gastrointestinal symptoms. In a study from Iran of 345 people, Blastocystis was actually more common in healthy individuals than in those with digestive complaints.
The picture gets more interesting in larger datasets. A global metagenomic analysis of 56,989 people across 32 countries found that carrying Blastocystis was associated with healthier diets, lower body mass index (BMI, a measure of weight relative to height), better lipid profiles, and lower levels of GlycA, a blood marker of systemic inflammation. People colonized with Blastocystis often have more diverse gut bacteria, sometimes considered a marker of a healthier microbiome.
These findings can feel contradictory: some research treats Blastocystis as a parasite to clear, while other research suggests its presence tracks with better health. Both can be true. Blastocystis is not a simple "good or bad" marker. Its impact depends on which subtype you carry, the state of your gut bacteria, your immune health, and whether you have other coinfections. A positive test in a healthy person with a balanced microbiome may mean little. The same positive test in someone with chronic diarrhea, weakened immunity, or unexplained urticaria carries very different weight.
When Blastocystis does cause symptoms, the most common are abdominal pain, loose stools or chronic diarrhea, bloating, flatulence, and constipation. Some people experience nausea or fatigue alongside gut complaints. In a series of patients with these symptoms treated with metronidazole, an antibiotic, many became asymptomatic and tested negative on follow-up.
Blastocystis is also detected at high rates in people with irritable bowel syndrome (IBS), with prevalence reaching up to 76% in some IBS cohorts. Detection in colonic aspirate samples taken during colonoscopy can find Blastocystis when standard stool tests miss it, and treating it has improved symptoms in selected IBS patients.
Chronic urticaria (hives) and unexplained itching or rash have been linked to Blastocystis in multiple studies. In one series of 104 urticaria patients, 61% tested positive for Blastocystis, and symptoms cleared after treatment with metronidazole.
If you have chronic hives or itching that has not responded to standard allergy treatment, checking for Blastocystis is a reasonable step that many dermatologists overlook.
In people with HIV, cancer, or other significant immunosuppression, Blastocystis behaves more like a clear pathogen. In a multicenter study of 1,245 people living with HIV, viral load and CD4 cell counts (markers of how active the virus is and how strong the immune response is) were better predictors of Blastocystis infection than other factors. Case reports describe severe disease, including ascitic infection in a patient with rectal carcinoma and large colonic ulcers in a traveler, both of which improved with metronidazole.
Not every Blastocystis carrier faces the same risk. Subtype identification, available with PCR-based testing, can help interpret what a positive result means.
| Subtype | What It Tends to Mean |
|---|---|
| ST1 | More often linked to symptoms in humans and greater intestinal pathology in animal models |
| ST2 | Repeatedly found in asymptomatic carriers and considered likely non-pathogenic |
| ST3 | The most common subtype globally; often found in healthy people but sometimes linked to symptoms |
| ST4 | More associated with infectious diarrhea, particularly in Europe |
| ST7 | Linked to lower gut bacterial diversity and pathogenic behavior in diarrheal patients |
Source: Popruk et al., 2021; Hussein et al., 2008; Deng et al., 2022; Bart et al., 2013.
What this means for you: a positive test that includes subtype information is more useful than presence/absence alone. If you test positive and have symptoms, knowing whether it is ST1, ST4, or ST7 (more concerning) versus ST2 (often benign) can help guide whether treatment is worth pursuing.
Blastocystis testing is qualitative: results are reported as detected or not detected, often with the subtype identified if PCR is used. There is no "normal range" or numerical cutoff. Some tests will report relative abundance, but no clinical guideline defines a level above which Blastocystis becomes pathogenic. Symptom severity does not consistently track with parasite quantity.
The single biggest reason for a misleading result is the testing method itself. Standard stool microscopy has low sensitivity for Blastocystis. Reviews show that PCR detects substantially more infections than microscopy or the routine ova-and-parasite exam. A negative result on a standard panel does not reliably exclude Blastocystis.
Blastocystis testing is not a marker you trend the way you would trend cholesterol or HbA1c, a measure of average blood sugar. The clinical question is binary at any given time: present or absent, with subtype if detected. The reason to retest is to confirm clearance after treatment or to recheck if symptoms return.
If you test positive and pursue treatment, retest 4 to 6 weeks after finishing the course to confirm clearance. If you test positive but stay asymptomatic and choose not to treat, there is no clear benefit to repeated retesting unless symptoms develop. If your initial test was microscopy-only and was negative but your symptoms persist, repeat with PCR rather than another microscopy exam.
A positive test alone is not a reason to start treatment. The decision depends on three things: whether you have symptoms, what subtype you carry, and whether other causes have been ruled out.
The standard antiparasitic treatments studied in trials include metronidazole and nitazoxanide, both of which require a prescription. A randomized trial in 168 patients with persistent diarrhea found nitazoxanide cleared the organism in 86.6% of cases versus a much lower rate with placebo. Other trials, however, found no symptom improvement with metronidazole versus placebo, suggesting that not every positive case benefits from antibiotics.
Evidence-backed interventions that affect your Blastocystis Hominis level
Blastocystis Hominis is best interpreted alongside these tests.